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ABSTRACT:
A major challenge in advanced-stage epithelial ovarian cancer (EOC) is prediction 
of chemoresistant relapse. Our aim was to identify a microRNA (miRNA) signature 
associated with early relapse in advanced-stage EOC patients. miRNA expression 
was assessed by microarray profiling in training (n = 55) and test (n = 30) sets 
selected on the basis of time to relapse (TTR), followed by internal quantitative 
reverse transcriptase-PCR validation on a set of 45 consecutive cases unselected 
for clinical response and external in silico validation on publicly available datasets. 
Thirty-two differentially expressed miRNAs in early vs. late relapsing patients 
were identified in the training set. In the test set, 8 of these, belonging to a cluster 
located on chrXq27.3, were down-modulated in early relapsing patients. Hierarchical 
clustering of the internal validation set according to chrXq27.3 miRNA expression 
associated low miRNA expression with shorter TTR (log-rank P=0.00074, HR 2.44). 
The cluster was an independent prognostic factor in both internal and external 
validation sets. Forced expression of chrXq27.3-cluster selected miRNAs in human 
EOC cellular models was associated to reduction of cell proliferation and increased 
sensitivity  to  cisplatin.  The  role  of  down-modulation  of  the  chrXq27.3  miRNA 
cluster in early relapse of advanced-stage EOC patients and its association to a 
reduced sensitivity to chemotherapeutic treatments warrant further investigation.
INTRODUCTION
Epithelial ovarian cancer (EOC) remains one of 
the most challenging areas of cancer research. Despite 
ongoing efforts to develop an effective screening 
strategy [1] and years of research into new treatments, 
the survival rate from EOC remains one of the lowest of 
all cancers [2]. The poor ratio of survival to incidence in 
EOC is a result of the high percentage of cases presenting 
at an advanced‑stage; the overall 5‑year survival rate 
is approximately 30% [1]. Standard treatment for 
advanced‑stage EOC is aggressive surgery followed 
by platinum‑taxane chemotherapy, with response 
rates of over 80% [3]. However, most of these patients 
will eventually relapse, with a median time to relapse 
(TTR) of 18 months. Several drugs are available to treat 
relapsing patients, although clinical responses remain 
short‑lived and lead to only marginal improvements in 
survival of patients with platinum‑resistant disease [4]. 
Therefore, there is a critical need for early identification Oncotarget 2011; 2:   1265 - 1278 1266 www.impactjournals.com/oncotarget
of patients with drug‑resistant cancers so that alternative 
therapeutic modalities can be offered. 
Normal human cells express thousands of 
non‑coding RNAs, including microRNAs (miRNAs), 
whose regulatory activity and alterations in expression 
contribute to the pathogenesis and progression of several 
human malignancies [5‑7]. As recently reviewed [8], 
a general down‑modulation of miRNA expression is 
observed in EOC compared to normal tissue, and the 
most frequently deregulated miRNAs are members of the 
let‑7 and miR‑200 families; the latter is involved in the 
epithelial mesenchymal transition and has been found to 
be de‑regulated in both early‑ and advanced‑stage EOC 
[9, 10]. Nonetheless, clear consensus miRNA signatures 
associated with EOC prognosis or prediction of response 
to conventional therapy have not yet described [8]. 
Recently, the results of an  integrated genomic 
analyses of a large cohort of advanced‑stage, high‑grade 
serous ovarian cancer has become publicly available [11]; 
in this Cancer Genome Atlas study, clustering of miRNA 
expression data identified three subtypes of tumors but 
no data of association with early relapse are at present 
available. 
With the objective of identifying a miRNA signature 
of EOC early relapse, a training set of samples from 
advanced‑stage EOC patients, selected for different 
residual  disease  and  TTR,  and  profiled  by  miRNA 
microarray analysis, has been characterized by a miRNA 
signature comprising a miRNA cluster located on 
Chromosome X and down modulated in early relapsing 
patients. A test set with similar clinical characteristics 
challenged with the identified miRNA signature confirmed 
that low expression levels of chrXq27.3 miRNAs 
cluster associated with an early relapse. Validation 
by  quantitative reverse transcriptase‑PCR (qRT‑PCR) 
showed that expression of the chrXq27.3 miRNA 
cluster correlated with clinical outcome in a cohort of 
consecutively collected samples. The association of low 
expression of chrXq27.3 miRNA cluster with a shorter 
TTR  was  confirmed  by  in  silico  analysis  of  publicly 
available datasets of advanced stage EOC patients with 
known clinical history. Finally, the functional role of three 
miRNAs was investigated using two human EOC cell 
lines, in which reduced cell proliferation and increased 
sensitivity to cisplatin (DDP) treatment was demonstrated 
after forced miRNAs expression.
Training set (n = 55) Test set (n = 30) Validation set (n = 45)
N° % N° % N° %
Age, years
median 56 53 50
range 30-78 25-74 25-85
Histology
Serous 40 73 22 73 27 60
Undifferentiated 4 7 3 10 4 9
Clear Cells 3 5 _ _ 3 7
Endometroid 3 5 5 17 4 9
Others + Mixed 5
a 9 _ _ 6
b 13
NA _ _ _ _ 1 2
Stage (FIGO)
III 45 82 25 83 37 82
IV 10 18 5 17 8 18
Grade
1-2 well/moderately differentiated 7
c 13 9
c 30 7 15
3, poorly differentiated 43 78 18 60 33 74
Undifferentiated 4 7 3 10 4 9
NA 1 2 _ 1 2
Amount of residual disease
NED 12 22 3 10 6 13
<1 cm, mRD 12 22 8 27 16 35
≥1 cm, GRD 31 56 19 63 23 51
Relapsing patients
d
Early 30 54 13 40 not a priori selected
Late 25 46 17 60 not a priori selected
Abbreviations: NA, not available. FIGO, International Federation of Gynecological and Obstetrics staging system. NED: not evident disease;
mRD: minimal residual disease; GRD: gross residual disease. Patients NED or w ith mRD are considered optimally debulked (OD).
a Including 4
mixed-type tumors and 1 Mullerian tumor.
b Including 5 mixed-type tumors and 1 mucinous tumor.
c Only 1 w ell-differentiated G1 case included.
d Early relapse:w ithin 12 or 6 months fromthe end of therapy for OD and sub-OD patients, respectively. Laterelapse: equal or longer than 36 or
12 months fromthe end of therapy for OD and sub-OD patients,respectively.
Table 1: Clinical and Pathologic CharacteristicsOncotarget 2011; 2:   1265 - 1278 1267 www.impactjournals.com/oncotarget
Figure 1: A miRNA expression profile distinguishes between EOC patients with early and late relapse. A) Heat map 
of hierarchical clustering analysis of patients from the training set based on the 32 miRNAs differentially expressed at FDR<10%. B) 
Hierarchical clustering of patients from test set challenged with the miRNA profile identified in the training set. Twenty-eight of 32 
miRNA were detected in the test set. A and B: columns, samples; rows, miRNA expression levels. Red, over‑expressed miRNAs; green, 
under-expressed miRNAs. C) Correlation between training and test sets for the fold changes of the 10 miRNAs identified as differentially 
expressed in both sets and that maintained a P value <0.01 in the test set (see also Table 2).
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RESULTS
Identification of a miRNA profile associated with 
early relapse in advanced‑stage EOC
The  strategy  for  identifying  a  miRNA  profile 
associated with early relapse was initially based on 
the selection of a training set of 55 advanced‑stage 
EOC from patients with a different clinical history of 
response to first-line chemotherapy. Thirty patients had 
early relapse, and 25 patients had late relapse (Table 
1). In this dataset, 744 miRNAs were detected and 
class comparison analysis, imposing a false discovery 
rate  (FDR)  <10%,  identified  an  expression  signature 
comprising 18 down‑modulated and 14 up‑modulated 
miRNAs in patients with early relapse (Figure 1A). Ten 
of the 18 down‑modulated miRNAs were located on 
chromosome X (chrXq27.3, X: 146.27‑146.36), and 
six of the 14 up‑regulated miRNAs were located on 
chr14q32.31 (Table 2). Analysis of association between 
miRNA expression and clinical parameters (stage, 
Training set 
a Test set 
b
miRBase
annotation
IlluminaID
Fold-
change 
late/early 
relapse
Parametric 
p-value
Fold-
change 
late/early 
relapse
Parametric 
p-value
Map 
Location
hsa-miR-513b ILMN_3168868 11.14 1.90E-06 5.67 0.00017 chrXq27.3
hsa-miR-514 ILMN_3168464 7.17 2.60E-06 4.84 3.00E-07 chrXq27.3
hsa-miR-508-3p ILMN_3168488 6.63 3.17E-05 7.71 5.00E-07 chrXq27.3
hsa-miR-202*:9.1 ILMN_3167129 6.04 2.65E-05 3.2 0.00012 NA
hsa-miR-509-3-5p ILMN_3168790 5.71 0.000392 chrXq27.3
hsa-miR-513a-3p ILMN_3168779 5.23 0.000256 chrXq27.3
hsa-miR-506 ILMN_3168328 5.07 0.0001 4.36 0.00318 chrXq27.3
hsa-miR-509-5p ILMN_3168789 4.92 6.11E-05 3.41 0.00295 chrXq27.3
hsa-miR-202* ILMN_3168871 4.38 0.002787 2.33 0.052874 chr10q26.3
hsa-miR-509-3p ILMN_3168363 3.79 0.00093 4.65 0.0006 chrXq27.3
hsa-miR-507 ILMN_3167727 2.75 0.00011 3.31 2.17E-05 chrXq27.3
hsa-miR-513a-5p ILMN_3168869 2.37 0.00061 2.15 0.00283 chrXq27.3
HS_141 ILMN_3167414 1.92 7.50E-06 NA
hsa-miR-339-3p ILMN_3168833 1.82 0.004224 1.01 0.969504 chr7p22.3
hsa-miR-32 ILMN_3167472 1.69 0.004243 0.79 0.113184 chr9q31.3
hsa-miR-191* ILMN_3167124 1.5 0.001467 1.13 0.36892 chr3p21.31
HS_138 ILMN_3167622 1.45 0.001171 1.07 0.751857 NA
hsa-miR-188-5p ILMN_3167745 1.44 0.003238 0.89 0.543601 chrXp11.23
hsa-miR-22* ILMN_3168621 0.72 0.002515 0.97 0.850966 chr17p13.3
hsa-miR-27b* ILMN_3168599 0.66 0.002082 0.71 0.077505 chr9q22.32
hsa-let-7f-1* ILMN_3167319 0.6 0.002563 0.95 0.818997 chr9q22.32
hsa-miR-15b* ILMN_3168693 0.59 0.00035 0.64 0.0061 chr3q25.33
hsa-miR-454 ILMN_3168319 0.57 0.001298 1.02 0.893015 chr17q.22
hsa-miR-411 ILMN_3167988 0.55 1.23E-05 1.36 0.058 chr14q32.31
hsa-miR-30c-2* ILMN_3168727 0.55 0.002809 0.97 0.927898 chr6q13
hsa-miR-139-5p ILMN_3166992 0.53 0.003255 0.87 0.678405 chr11q13.4
hsa-miR-299-5p ILMN_3167913 0.51 0.000767 1.52 0.141925 chr14q32.31
hsa-miR-493* ILMN_3167972 0.5 0.000377 1.12 0.472174 chr14q32.2
solexa-499-2217 ILMN_3168900 0.5 0.003835 0.91 0.289138 NA
hsa-miR-485-3p ILMN_3168166 0.47 0.000859 0.74 0.303974 chr14q32.31
hsa-miR-656 ILMN_3168467 0.4 2.43E-05 chr14q32.31
hsa-miR-494 ILMN_3168446 0.35 1.13E-05 0.99 0.981626 chr14q32.31
a32 miRNAs were differentially expressed at afalse discovery rate < 10% and detection p-value < 0.05 between
late or early relapsing patients: 29 were mature miRNAs from miRbase v12.0 and 3 were putative miRNAs
derived from deep sequencing approaches (see description of Illumina platform on GEO repository; GEO
accession:GPL8179).
b Empty cells: miRNAs identified in training set and filtered out in test set (detection p-values greater than the
thresholdadopted in the analysis for more than 50% of samples).
In bold: differentialexpressedmiRNAs validated in the test set.
Table 2: miRNAs differentially expressed between late and early relapsing patients in training and test sets.Oncotarget 2011; 2:   1265 - 1278 1269 www.impactjournals.com/oncotarget
grading and debulking) showed that, by class comparison 
and imposing a FDR<10%, no significant modulation of 
miRNA was detected between stage III and IV lesions, 
well and moderately versus poorly differentiated and 
undifferentiated tumors, or optimally debulked (OD) 
versus sub‑OD patients. 
A test set (13 and 17 patients with early and late 
relapse, respectively), selected in agreement with 
debulking status and TTR criteria adopted for the training 
set, was used to validate the microarray data obtained 
with the training set. As listed in Table 1, there were no 
differences in age, stage, grade, histology, or debulking 
status of patients between the training and test sets, 
and only the median follow‑up period was longer in 
the latter (49 versus 64 months, respectively). Profiling 
of the test set detected 741 miRNAs, including 28/32 
miRNAs found differentially expressed in the training 
set. Unsupervised hierarchical clustering analysis, based 
on  the  miRNA  signature  identified  in  the  training  set, 
correctly classified test set patients according to relapse in 
90% of cases (27/30) (Figure 1B). Ten of these miRNAs 
showed  significant  differential  expression  (P <0.01), 
and all but one were down‑regulated in patients with 
early relapse (Table 2). Among these, eight were located 
in chrXq27.3, representing a highly correlated and 
co‑expressed miRNA cluster. The fold change of the 10 
differentially expressed miRNAs between patients with 
early and late relapse was highly correlated (R2= 0.838) 
in the two clinical sets (Figure 1C). 
Thirty‑nine samples belonging to training set and 24 
samples belonging to test set were analyzed by qRT‑PCR 
for expression of the mature form of miR‑506 showing an 
intermediate fold‑change expression in training and test 
set. Microarray data were validated and a high correlation 
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Figure 2: qRT‑PCR validation of the chrXq27.3 miRNA cluster. A) Comparison of miR‑506 expression obtained by miRNA 
expression profile and qRT-PCR on 39 samples (17 early and 22 late relapse) from training set (upper panels) and 24 samples (10 early and 
14 late relapse) from test set (lower panels). B) Comparison of chrXq27.3 miRNA cluster expression obtained by miRNA expression profile 
(upper panels) and qRT‑PCR (lower panels) on the 24 samples from test set. P values of differential expression between late and early relapsing 
patients are reported.Oncotarget 2011; 2:   1265 - 1278 1270 www.impactjournals.com/oncotarget
between data obtained with the two assays was observed 
in both training and test set (R2 was 0.8423 and 0.752 
respectively; Figure 2A). Samples from test set were then 
analyzed by qRT‑PCR for expression of the mature forms 
of the other miRNAs belonging to the chrXq27.3 cluster 
and down‑regulated in early relapsing patients. As in the 
case of miR‑506, the microarray and qRT‑PCR showed a 
significant correlation median (R2 = 0.661; Figure 2A‑B). 
miR‑335*, not belonging to the chrXq27.3 cluster and not 
differentially expressed among the 744 miRNA detected 
in the training set, was selected and validated as unrelated 
control (R2 =0.498; data not shown). 
Down‑regulation  of  chrXq27.3  cluster  is 
associated with shorter TTR 
We then used qRT‑PCR to analyze the expression 
of the 8  chrXq27.3 miRNAs in a third cohort of 45 
advanced‑stage consecutive EOC cases (validation set) 
that were not previously selected for response to first-line 
treatment (see Table 1). In this clinical set (median of 
follow‑up period = 35 months), there were no differences 
in age, stage, grade, histology, or debulking status 
compared to the other cohorts. Unsupervised clustering 
classified  validation  set  patients  into  three  clusters 
(Figure 3A): clusters 1 and 2 (n = 16 and 7, respectively) 
both showed low expression of chrXq27.3 miRNAs, 
while cluster 3 (n = 22) had high expression of chrXq27.3 
miRNAs. Clusters 1 and 2, as determined by both multi 
dimensional scaling (MDS) and principal component 
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Figure 3: Down‑regulation of chrXq27.3 miRNAs associated with shorter TTR. A) Unsupervised clustering of validation set 
samples, according to chrXq27.3 miRNA expression by qRT‑PCR. B) Multidimensional Scaling (MDS) analysis. MDS analysis preserves 
the pair-wise similarities between samples in a three-dimensional graphical representation without forcing the samples into specific clusters 
as done by hierarchical clustering. The P‑value of global clustering test based on three components (covering 92% of total variation) 
obtained by Euclidean distance is <0.001. MDS was generated using uncentered correlation. C) Principal component analysis. The box plot 
shows the eigenvalues for the 3 clusters based on the first principal component accounting for 44.1% of the overall variability of the miRNA 
data across the 45 samples. Kruskal‑Wallis test: P‑value< 0.0001. D) Kaplan‑Meier survival curves of patients included in the validation set 
stratified according to chrXq27.3 cluster classification, clusters 1 and 2 (dotted line) and cluster 3 (continuous line). Curves were compared 
using the log‑rank test; P = 0.00074. Oncotarget 2011; 2:   1265 - 1278 1271 www.impactjournals.com/oncotarget
analysis (PCA) analyses, had a global expression 
comparable and distinct from cluster 3 (Figures 3B 
and 3C); thus, they were considered together in further 
analyses. Kaplan‑Meier analysis indicated that patients 
belonging to clusters 1 and 2 experienced a shorter TTR 
(log‑rank, P = 0.0007; HR = 2.44, 95%CI: 1.25‑4.76). The 
median TTR was 8 and 21 months for patients belonging 
to clusters 1 and 2 (low chrXq27.3 miRNA expression) 
and cluster 3 (high chrXq27.3 miRNA expression), 
respectively (Figure 3D). 
Using miRNA cluster expression and surgical 
debulking as covariates, a bivariable Cox regression 
analysis performed on the type II EOC subgroup 
of patients (n  = 40, excluding samples with grade 1 
tumors and clear cell or mucinous histotypes) indicated 
down‑regulation of chrXq27.3 miRNAs as a possible 
independent prognostic indicator of early relapse (HR = 
2.33; 95% CI: 1.06‑5.12, P = 0.035). As expected, the 
prognostic relevance of surgical debulking was confirmed 
(HR = 4.3, 95% CI: 2.03‑9.27, P = 0.00015) in this model.
In silico validation of the prognostic impact of 
chrXq27.3 miRNAs 
The  TGCA  data  set  of  miRNA  profile  [11]  was 
used for external validation restricting the analyses 
to the 360 stage III and IV EOC samples for whom 
complete survival data are available. On this subset of 
samples the expression of all the 8 miRNAs belonging 
to chrXq27.3 was detected. Unsupervised analysis 
on  the  miRNome  profile  provided  evidence  that  the 
miRNAs located on chrXq27.3 are members of a highly 
correlated and co‑expressed miRNA cluster. In particular 
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Figure 4: In silico analysis on TGCA dataset. A) Unsupervised clustering of whole miRNome profile in the TGCA study. Only stage 
III and IV ovarian cancers with TTR data were included in the analysis and clustered in a heat map diagram. The heat map reveals the major 
miRNA patterns present in the array matrix and points out a highly correlated cluster of thirteen miRNAs all belonging to chrXq27.3. A 
magnification of the 8 chrXq27.3 miRNAs associated to TTR in our work is shown (samples were sorted following the order established in 
the unsupervised cluster). B) Multidimensional Scaling (MDS) analysis. Patients included in the TGCA dataset were stratified according to 
the first principal component (PC1) retaining most of the variability of the data (74%). Two groups of patients were included in the MDS 
analysis: first PC1 quartile (green) and last PC1 quartile (red). The MDS analysis was performed based on the expression of the 8 chrXq27.3 
miRNAs. The P‑value of global clustering test based on three components (covering 90% of total variation) obtained by Euclidean distance 
is <0.001. C) Kaplan‑Meier survival curves related to the two sub‑groups of patients.  First PC1 quartile (dotted line) and last PC1 quartile 
(continuous line); curves were compared using the log‑rank test; P = 0.0092.Oncotarget 2011; 2:   1265 - 1278 1272 www.impactjournals.com/oncotarget
six out of eight chrXq27.3 miRNAs (miR‑506, miR‑507, 
miR‑508‑3p, miR‑509‑3p, miR‑509‑5p and miR‑514) 
showed Pearson’s correlation greater than 0.95 (Figure 
4A). Principal component analysis was applied on the 
expression  of  the  8  chrXq27.3  miRNAs  and  the  first 
component (PC1) covering 74% of total variation in 
the data was used for survival analysis. Based on PC1, 
patients were split in quartiles and we considered two 
groups with low and high expression intensities of 
chrXq27.3  miRNA  cluster  corresponding  to  the  first 
(n=90) and the fourth (n=90) quartile, respectively. 
The  two  groups  represent  patients  with  well-defined 
expression pattern as highlighted by MDS analysis 
(Figure  4B).  Kaplan-Meier  analysis  confirmed  that 
patients with low expression of chrXq27.3 miRNA cluster 
experienced shorter progression free survival (log‑rank, 
P=0.0092; HR= 1.57, 95%CI: 1.12‑2.22). The median 
TTP was 14 and 19 months for patients with low and high 
chrXq27.3 miRNA expression, respectively (Figure 4C). 
Using miRNA cluster expression and surgical debulking 
as covariates, a bivariable Cox regression analysis 
indicated down‑regulation of chrXq27.3 miRNAs as a 
possible independent prognostic indicator of early relapse 
(HR = 1.85; 95% CI: 1.28‑2.66, P = 0.001). 
Over‑expression of cluster chrXq27.3 miRNAs in 
EOC cell lines: effects on survival and platinum 
sensitivity
The association of chrXq27.3 miRNA cluster 
lower expression with shorter TTR, suggested a possible 
involvement of these miRNAs in cell growth and 
response to therapy. 
Three miRNAs belonging to the chrXq27.3 cluster, 
miR‑513b, miR‑506 and miR‑513a‑5p, were selected 
according to their different fold change expression 
observed by microarray and class comparison analysis 
on EOC samples (see Table 2) and their expression 
was forced by transient transfection in two EOC cell 
lines, SKOV3 and OAW42. The miRNAs increased 
expression  level  upon  transfection  and  its  specificity 
was demonstrated by qRT‑PCR (supplementary Figure 
1). Forced expression of miR-506 induced a significant 
reduction of cell proliferation in both cell lines (39±3% 
and 57±7%, relative to control cells transfected with the 
scrambled miRNA, in SKOV3 and OAW42 respectively), 
whereas miR‑513a‑5p and miR‑513b showed a less 
intense, albeit significant anti proliferative effect (37±5% 
and 17±6% of reduction respectively) on OAW42 cells 
only (Figure 5A).
A relevant increase of cells blocked in the G1 phase 
in both cell lines (increase range 16% ‑ 30% compare to 
control in three independent experiments) was observed 
upon forced expression of miR‑506, while increase of 
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cell death, evaluated as cellular debris, was observed in 
OAW42 cells only (Figure 5B). Forced expression of 
the other two miRNAs in SKOV3 cells, mirroring the 
marginal effects on cell proliferation, did not substantially 
affect cell cycle dynamics. In miR‑513a‑5p‑transfected 
OAW42 cells, accumulation of cells in the G1‑phase was 
evident and was accompanied with a slight increase (8%) 
of cells blocked in the G2‑M phase. In agreement with the 
weaker anti‑proliferative effect obtained on OAW42 cells 
after miR‑513b‑transfection, only a marginal increase 
(5%) of G1‑phase and a 10% increase of cells blocked in 
G2‑M phase was observed as compared to the other two 
miRNAs (Figure 5B). 
Based on these data, OAW42 cell line was 
selected to assess the effect of the forced expression 
of the three miRNAs on response to DDP treatment. A 
growth inhibition of 58±8% (Figure 6A) was observed 
in scrambled miR‑transfected (control) cells exposed 
to a DDP concentration that, according to our previous 
knowledge, corresponds to IC50 in parental cells. DDP 
sensitivity at concentration ranging from 10x10‑6 to 
0.03x10‑6  M  was  significantly  increased  (P=0.001)  as 
assessed by sulphorodamine‑B (SRB) assay following 
forced expression of miR‑506 (Figure 6B). Also 
miR-513a-5p  and  miR-513b  caused  a  significantly 
increased DDP sensitivity. At a DDP concentration 
corresponding to the IC50 in scramble‑transfected cells, 
cell growth was further inhibited following 54±5% 
following miR‑513a‑5p and 66±14% by miR‑513b 
transfection (Figure 6C).
In miRNA‑transfected‑DDP‑treated cells, the effects 
on cell cycle resulted more variable and less informative. 
As a general observation, all the three miRNAs induced, 
although at different extent, an accumulation of cells in 
G1-phase  (figure  6D).  Forced  expression  of  miR-513b 
caused a higher accumulation of cells in G2‑M phase 
as compared to miR‑506 and miR‑513a‑5p whereas 
forced expression of miR513a induced a more consistent 
increase of cell debris as compared to the other two 
miRNAs. 
DISCUSSION
Therapeutic  decisions  in  EOC  after  first-line 
chemotherapy should be based on the risk of tumor 
relapse. Although for solid tumors such as breast and 
prostate  cancer,  molecular  profiling  of  primary  tumors 
can help in defining risk of relapse, prediction of drug 
response, and time to relapse [12, 13], the heterogeneous 
clinical and pathological characteristics of advanced‑stage 
EOC patients make it difficult to exploit genome-wide 
information to stratify patients according to prognosis 
[14]. However, there is accumulating evidence that 
miRNAs may be of higher utility than mRNA expression 
due to their master regulatory role, and examples of 
their utility as both biomarkers and therapeutic targets 
have been reported for other solid tumors [15]. To our 
knowledge,  this  is  the  first  study  to  date  specifically 
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designed to identify miRNAs as markers of early 
relapse in advanced‑stage EOC. Using 2 independent 
cohorts and microarray analysis we identified a cluster 
of miRNAs, located at chrXq27.3 in a region <0.5 Mb, 
that are always down‑modulated or almost switched‑off 
in patients that experience early relapse. Validation of 
this result by qRT‑PCR in a set of consecutively collected 
cases highlighted a significant correlation between low 
expression of chrXq27.3 miRNAs and clinical outcome. 
Our cohorts of patients, which were 
well‑characterized for clinical and pathological 
characteristics, came from a single institution; therefore, 
efforts were focused in reducing the potential over-fitting 
of data [16]. Training and test sets, selected with the same 
criteria and analyzed on the same miRNA microarray, 
were independently obtained from institutional tissue 
bank and archival pathologic repository, respectively. Due 
to the fact that the quality of RNA extracted from FFPE 
tissues (test set) was not as high as that of RNA extracted 
from frozen tissues (training set), the number of samples 
in the test set was quite limited; however, both sets were 
equally reliable when used for qRT‑PCR measurements. 
For validation of chrXq27.3 miRNA cluster, we used 
a third cohort of consecutive frozen samples from 
advanced‑stage EOC and qRT‑PCR as detection assay. 
Our criteria for case selection only partially 
overlap those adopted in the Cancer Genome Atlas 
(TCGA) project for EOC which considered only 
clinically annotated stage II‑IV high‑grade serous ovary 
cancers [11]. In our analysis, the selection was driven 
by different TTR in stage III‑IV cases without prior 
selection by grade and histotype. However, taking into 
account the significant progress in the histopathological 
sub-classification of EOC [17], the majority of our cases 
could  be  classified  as  so-called  type  II  tumors  (grade 
2‑3; subtype: serous, undifferentiated and endometrioid), 
characterized by very aggressive behavior [18]. Indeed, 
only 1/130 cases was grade 1, 5/130 were clear cells and 
1/130 was mucinous. In the case of the validation set, 
unselected for response to therapy, bivariate analysis 
with miRNA cluster expression and surgical debulking 
as covariates identified the chrXq27.3 miRNA cluster as 
a potential independent predictor of early relapse in type 
II EOC tumors (40/45 cases). This result was in silico 
validated  on  the  TGCA  miRNA  profile  [11]  although 
the two platforms used for the analysis were different 
and a clear standardization in platform fabrication, assay 
protocol, and analysis methods is still lacking. 
The finding that a lower expression of the miRNA 
cluster chrXq27.3 is consistently associated with shorter 
TTR also when the signature was challenged on a wider 
and independent publicly available dataset suggested a 
possible involvement of these miRNAs in cell growth 
and response to therapy. Members of this cluster have 
been  previously  identified  as  down-modulated  in 
advanced‑stage and/or high grade lesions [19], and one 
miRNA belonging to the cluster (miR‑509) was found to 
be down‑modulated in chemoresistant advanced‑stage 
EOC [20], supporting the relevance of our results.
Our in vitro data essentially support the proposed 
antiproliferative role for these miRNA although a quite 
heterogeneous effect in terms of efficacy and efficiency 
has been observed when considered individually. In 
particular a role for miR‑506 in favoring blockade of cell 
cycle in G1 phase and inducing cell death is suggested 
by our data. The role of miR‑506 in tumor cells has not 
yet  clearly  defined  and  probably,  as  already  described 
for other miRNAs, its effect could be cell and tumor 
type dependent. Indeed recent literature, in accordance 
with our observations, suggests a putative role as an 
anti‑oncogenic miRNA in human bronchial epithelial 
cells where miR‑506 expression regulates cell growth and 
proliferation [21] but also its over expression has been 
recently related to hydroxycamptothecin resistance in a 
colon cancer cell line by direct inhibiting expression of 
Peroxisome proliferator‑activated receptors (PPARs) [22]. 
The other two miRNAs (miR‑513a‑5p and miR‑513b) 
were selected among the other miRNAs belonging to 
the cluster on the basis of their differential fold change 
expression. However, their forced expression only 
partially reflects the effects observed with miR-506. Of 
note, two different analysis both performed on available 
unselected EOC samples (validation set and TCGA data) 
indicate that miR‑513a‑5p and miR‑513b form a separate 
subcluster within the Xq.27.3 cluster. Taken together, 
expression and biological data suggest that within 
the  identified  cluster,  the  individual  miRNAs  could 
contribute to the overall cell behavior with only partially 
common  mechanisms  of  regulation.  The  identification 
and validation of target genes of each individual members 
of the cluster could clarify this aspect and thus deserve 
further and specific investigation. 
Eight out of 10 miRNAs, whose expression is 
down‑regulated in patients with adverse outcome, 
localized in a less than 0.5Mb cluster on chrX. A variety 
of  mechanisms  including  amplification,  deletion  or 
mutation may contribute to the deregulation of miRNA 
expression (reviewed in [23]). The primary regulatory 
mechanism of miRNA expression however, seems to be 
a transcriptional control essentially exerted by epigenetic 
silencing (reviewed in [24]). The availability of TGCA 
data prompted us to analyze in silico the methylation 
pattern of ChrX. Despite the continuous update of the 
platforms  and  the  increase  in  the  specific  probes,  still 
the coverage of our region of interest, i.e Xq27.3, is 
limited. However, we observed that the region Xq27‑ 
Xq28 was among the most frequently ipermethylated 
(Supplementary Figure 2). Although further analysis is 
needed, it seems likely that methylation play some role in 
the observed downregulation of miRNA cluster. 
Due to the stringent criteria adopted for selection 
of training and test sets, we cannot exclude that, in Oncotarget 2011; 2:   1265 - 1278 1275 www.impactjournals.com/oncotarget
addition to the validated miRNA cluster, other miRNAs 
are involved in drug response. Further studies using 
completely independent cohorts of patients from other 
institutions are clearly needed. In this context, the miRNA 
profiling of samples from a randomized clinical trial [25] 
is currently under investigation.
Taken together, the present data open the possibility 
of a new mechanistic hypothesis of gene regulation 
exerted by the chrXq27.3 miRNA cluster in EOC. The 
identified miRNA cluster, hopefully associated with other 
newly discovered miRNAs, may be applied in the context 
of clinical trials, as a potential marker of drug response in 
advanced‑stage EOC patients.
MATERIALS AND METHODS
Patients and biological materials
A total of 130 patients with advanced‑stage 
EOC were included in the study. All these patients 
underwent primary surgery at the Fondazione IRCCS 
Istituto Nazionale dei Tumori (INT) and had biological 
material available for molecular analysis, as well as 
complete clinical data and follow‑up information. The 
Institutional Review Board approved the use of surgical 
specimens (immediately snap‑frozen after surgery and 
stored  at  -80°C),  formalin-fixed  paraffin-embedded 
(FFPE) tissue blocks, and clinical data. The study was 
performed on tumor samples collected at surgery before 
chemotherapeutic treatment from three independent 
patient cohorts (training, test and validation sets) 
undergoing primary surgery between 1990 and 2008 and 
matched for time of diagnosis. All patients underwent 
exploratory laparotomy for diagnosis, staging, and 
debulking, and based on the extent of residual disease, 
patients were divided into three groups: no evident 
disease (NED); minimal residual disease (mRD, 
residual tumor <1 cm) and gross residual disease (GRD, 
residual tumor ≥1 cm). Patients NED or with mRD were 
considered optimally debulked (OD). Tumor staging 
was in accordance with the criteria of the International 
Federation of Gynecology and Obstetrics (FIGO). 
After surgery, patients received treatment with standard 
platinum‑based therapeutic schedules (platinum without 
taxanes; platinum and paclitaxel) according to the time of 
accrual. Time to relapse (TTR) was the time in months 
from  completion  of  chemotherapy  until  first  evidence 
(clinical, instrumental or biological) of disease recurrence 
(if a complete response was achieved) or progression. 
Standard post‑chemotherapy surveillance included 
routine physical examinations, serum CA‑125 levels, and 
computed tomography scanning as clinically indicated. 
Follow‑up time was the interval between diagnosis and 
date of death or the last information in medical records. 
Samples from training and validation sets were collected 
at the time of primary surgery and immediately frozen, 
samples from the test set were FFPE. Tumor content of 
all specimens was assessed by hematoxylin and eosin 
staining and all samples selected for miRNA analysis had 
>70% tumor cellularity and <20% necrosis. Patients from 
training (55 samples) and test (30 samples) sets were 
selected on the basis of residual disease after primary 
surgery [26]. To explore miRNA expression association 
with chemotherapy response, patients were also selected 
according to TTR as: patients with early relapse when 
the TTR was shorter than 12 (OD) or 6 (sub‑OD) 
months; patients with late relapse when TTR was equal 
or longer than 36 (OD) or 12 (sub‑OD) months. Patients 
in the validation set (45 samples) were selected from a 
consecutive case material on the basis of availability of 
both biological samples and clinical data without clinical 
restriction, but at an advanced-stage; patients reflected the 
age at diagnosis, stage, tumor grade, and surgical outcome 
of individuals typically diagnosed with advanced‑stage 
EOC with a median TTR of 16 months [27]. Table 1 
summarizes the clinical and pathologic characteristics of 
patients. Taking into account the new EOC classification 
[28], our case materials were mainly composed by Type 
II tumoros, indeed Type I tumors represented less than 
10% in each set, being: 3 cases (1 low‑grade serous 
and 2 clear cell tumors) present in training set; one low 
grade endometrioid tumor present in test set; and 4 cases 
(3 clear cell and 1 mucinous) in validation set. All these 
tumors were at stage III.
miRNA analysis
RNA extraction from frozen or FFPE tissues, 
quality assessment, miRNA hybridization conditions, 
preprocessing, and miRNA data analysis were performed 
as detailed in the Supplementary material. Mature 
miRNAs  were  amplified  [29]  and  labeled  probes  were 
hybridized on Illumina miRNA BeadChips Array. 
The microarray dataset and clinical information were 
deposited in the Gene Expression Omnibus database 
(experiment number GSE25204) according to MIAME 
(minimum information about a microarray experiment) 
guidelines. TaqMan microRNA assays from Applied 
Biosystems and Exiqon were used to quantify mature 
miRNAs. qRT‑PCR validation and Taqman Assays are 
described in the Supplementary material.
EOC cell lines and miRNA transfection
The OAW42 cell line (serous histotype, kindly 
provided by Dr. A. Ullrich, Max‑Planck Institute, 
Germany,  and  verified  in  house  for  identity  by 
microsatellite analysis) was maintained in MEM 
supplemented with 10% (v/v) fetal calf serum, 2 mmol/L Oncotarget 2011; 2:   1265 - 1278 1276 www.impactjournals.com/oncotarget
L‑glutamine (Sigma) and 1% non‑essential amino 
acids  (100X  stock;  Euroclone,  Italy)  in  a  humidified 
chamber (5% CO2, 37°C). The SKOV3 cell line, (serous 
histotype, from ATCC and verified in house for identity 
by microsatellite analysis) was maintained in RPMI 
1640 (Sigma Aldrich) with 10% fetal calf serum (FCS) 
(Hyclone, Logan, UT) and 2 mmol/L glutamine in a 
5% CO2  humidified  atmosphere  at  37°C.  Cells were 
confirmed to be mycoplasma-free. Ectopic expression of 
miR‑506, miR‑513a‑5p and miR‑513b was pursued by 
exposing EOC cell lines to 20 nM miRNA precursors, 
purchased as a pre‑miR molecule (Ambion, Austin,TX). 
Scrambled Pre‑miR molecules (Pre‑miR Negative 
Controls; Ambion) were used as a control. Transfection 
was carried out using Lipofectamine2000 (Invitrogen), 
according to the manufacturer’s protocol. The effect of 
ectopically expressed miRNAs was evaluated at day 3 
after 4‑h of transfection by assessing miRNAs levels by 
qRT‑PCR. 
Proliferation assay and drug treatment
The day after miRNAs transfection, OAW42 cells 
were exposed for 7h to cis‑platinum (DDP) (TEVA Italia 
s.r.l) at serial dilution starting from 10x10‑6 to 0.03x10‑6 
M for Sulforhodamine B (SRB) assay and at 1x10‑6 M, 
corresponding to inhibiting concentration 50 (IC50) 
according to our previous experience [30], for other drug 
treatment assays. The effects of miRNA transfection and 
DDP treatment on cell proliferation were assessed 72h 
after transfection by Trypan Blue exclusion assay or by 
SRB assay. For SRB assay cells were seeded in 96‑well 
flat-bottom  plates  at  an  initial  concentration  of  5,000 
cells per well in complete medium. Without removing the 
cell culture supernatant, cells were fixed by incubation 
for 1 h at 4°C with trichloroacetic acid (TCA) at the 
final  concentration  10%  (w/vol).  Following  extensive 
washing in water, cells were stained for 30 min with 
0.4% (w/v) SRB dissolved in 1% acetic acid. Wells were 
rinsed with 1% acetic acid and air dried. Bound dye was 
solubilized with 10 mM Tris base (pH 10.5) in a shaker. 
The OD was measured at 550 nm in a microplate reader 
(BIORAD,model 550).
Cell cycle evaluation
Cell cycle was analysed by flow cytometry. Cells 
were harvested in PBS containing 2 mM EDTA, washed 
once with PBS, fixed in iced ethanol 70% and incubated 
with 50mg/ml PI (Sigma) plus RNAse 0.5 mg/ml for 
30 min at 4°C in the dark. Stained nuclei were analysed 
with a FACSCalibur (Becton & Dickinson), and the data 
analysed using ModFit cytometry Analysis Software 
(Becton‑Dickinson). 
Bioinformatic analyses
Two publicly‑available datasets reporting miRNA 
expression and clinical annotated data were identified at 
the best of our knowledge and downloaded from the web: 
GSE27290 (available on GEO repository, [31]) and the 
Cancer Genomics Atlas (TGCA, [11]) study available at 
http://tcga‑data.nci.nih.gov/docs/publications/ov_2011/. 
The former data set consists of 62 diagnosed patients 
with stage III or IV serous ovarian cancer, while the latter 
reports  the  profiling  of  489  high-grade  serous  EOCs. 
Although both studies were generated using the Agilent 
platform, GSE27290 was profiled on a pre-commercial 
version of miRNA chips (GPL7341) designed on 
miRBase 9.1. Due to the incomplete presence of miRNAs 
belonging to the chrXq27.3 cluster of our interest and the 
differences in miRBase annotation between GPL7341 
and our Illumina platform, GSE27290 was not considered 
for  further  analyses.  TGCA  profiling  was  performed 
on 8x15Kv2 chip designed on miRBase10.1. Time to 
progression  (defined  as  the  interval  from  the  date  of 
initial surgical resection to the date of progression, date 
of recurrence, or date of last known contact if the patient 
was alive and has not recurred) was used as the primary 
end point. 
STATISTICAL ANALYSIS
Class comparison, hierarchical clustering, 
muldimensional scaling (MDS), global test of clustering, 
and heat map analyses were performed using BrB 
ArrayTools_v4.1.0‑stable release (Simon, R. and Lam, 
AP;  http://linus.nci.nih.gov/BRB‑ArrayTools.html). 
Principal component analysis (PCA) was performed using 
the open‑source PCA module of MeV (MultiExperiment 
Viewer, v4.6; http://mev.tm4.org), developed at The 
Institute for Genomic Research. The clinical and 
pathological characteristics of the three sets of patients 
were compared by Fisher’s exact test. Levels of miRNA 
and gene expression were compared by a Student’s t test. 
The linear relationship between variables was estimated 
by  Pearson’s  coefficient  of  correlation  (r)  and  R2 
coefficient of determination. We assessed the association 
of miRNA expression with TTR. 
TTR curves were generated by the Kaplan Meyer 
method and differences between curves were compared 
using a non‑parametric (log‑rank) test and hazard ratios 
and  95%  confidence  intervals  were  also  computed.  A 
bivariable Cox regression model was used to evaluate 
the prognostic impact of miRNAs expression taking 
into account the effect of surgical debulking. A two level 
classification was used for both miRNAs expression and 
surgical debulking. P values of all statistical tests were 
two sided. GraphPadPrism v5 (GraphPad software, La 
Jolla US) and R statistical language version 2.11 (URL Oncotarget 2011; 2:   1265 - 1278 1277 www.impactjournals.com/oncotarget
http://www.R‑project.org) were used for statistical 
analyses.
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